Exscientia (NASDAQ:EXAI) Hits New 12-Month Low at $4.13

Exscientia plc (NASDAQ:EXAI - Get Free Report)'s share price hit a new 52-week low during trading on Wednesday . The company traded as low as $4.13 and last traded at $4.16, with a volume of 213422 shares traded. The stock had previously closed at $4.38.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on EXAI shares. Morgan Stanley reissued an "equal weight" rating and issued a $7.00 price target on shares of Exscientia in a research note on Monday. Bank of America downgraded shares of Exscientia from a "buy" rating to a "neutral" rating and reduced their price target for the company from $11.00 to $9.00 in a research note on Friday, January 5th.

Exscientia Trading Down 5.7 %

The firm has a market cap of $499.28 million, a price-to-earnings ratio of -2.96 and a beta of 0.78. The company's 50 day simple moving average is $5.73 and its 200 day simple moving average is $5.85. The company has a debt-to-equity ratio of 0.05, a current ratio of 6.22 and a quick ratio of 6.22.

Exscientia (NASDAQ:EXAI - Get Free Report) last posted its quarterly earnings results on Thursday, March 21st. The company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.02. Exscientia had a negative net margin of 737.10% and a negative return on equity of 36.44%. The company had revenue of $3.10 million during the quarter, compared to analysts' expectations of $41.63 million. As a group, research analysts expect that Exscientia plc will post -1.76 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Exscientia

A number of institutional investors and hedge funds have recently added to or reduced their stakes in EXAI. Bank of New York Mellon Corp increased its stake in Exscientia by 26.4% in the third quarter. Bank of New York Mellon Corp now owns 155,097 shares of the company's stock valued at $701,000 after purchasing an additional 32,373 shares during the period. Banque Pictet & Cie SA acquired a new position in shares of Exscientia in the third quarter valued at approximately $1,040,000. Platinum Investment Management Ltd. raised its stake in shares of Exscientia by 10.2% during the third quarter. Platinum Investment Management Ltd. now owns 4,395,058 shares of the company's stock worth $19,866,000 after purchasing an additional 405,426 shares during the last quarter. Jump Financial LLC acquired a new stake in shares of Exscientia during the third quarter worth $165,000. Finally, Mitsubishi UFJ Trust & Banking Corp grew its position in Exscientia by 6.0% in the 3rd quarter. Mitsubishi UFJ Trust & Banking Corp now owns 203,970 shares of the company's stock valued at $922,000 after buying an additional 11,570 shares during the last quarter. Hedge funds and other institutional investors own 41.58% of the company's stock.

Exscientia Company Profile

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.